For your Treatment-Naïve patients
Two fully powered clinical trials with more that 1,400 treatment-naïve patients combined. Dovato demonstrated non-inferior efficacy vs DTG + TDF/FTC in treatment-naïve patients at 144-weeks1
This browser is no longer supported.
To provide you with the best possible experience, we kindly ask you to switch to a supported browser:
Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.4
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.
Date of preparation: July 2021 PM-IE-DLL-WCNT-200016